Efficacy and Safety of Ipratropium Bromide Plus Fenoterol Inhaled Via Respimat® Soft Mist™ Inhaler vs. a Conventional Metered Dose Inhaler Plus Spacer in Children with Asthma

Pediatric Pulmonology

Volumn 37, Issue 3, 2004, Pages 264-272

  Von Berg, Andrea ^a,g   Jeena, Prakash M ^b   Soemantri, Peter A ^c   Vertruyen, André ^d   Schmidt, Peter ^e   Gerken, Fronke ^e   Razzouk, Hassan ^f  

^a Marien Hospital GmbH   (Germany)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Arzt für Kinderheilkunde   (Germany)

^d Sint Vincentiusziekenhuis   (Belgium)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f Clin Pneumo Allergol Les Acacias   (France)

^g Children's Hospital Marienhospital Wesel   (Germany)

Author keywords

Bronchodilators; Childhood asthma; Fenoterol; Ipratropium; Respimat; Soft mist inhaler

Indexed keywords

BRONCHODILATING AGENT; CHLOROFLUOROCARBON; FENOTEROL PLUS IPRATROPIUM BROMIDE;

ADOLESCENT; ARTICLE; ASTHMA; BRONCHITIS; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FLU LIKE SYNDROME; HEADACHE; HUMAN; INHALER; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METERED DOSE INHALER; MULTICENTER STUDY; NEBULIZATION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EQUIPMENT DESIGN; FEMALE; FENOTEROL; HUMANS; IPRATROPIUM; MALE; METERED DOSE INHALERS; TREATMENT OUTCOME;

EID: 1542373594     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10428     Document Type: Article

References (27)

1. Mannino DM, Homa DM, Pertowski CA, Ashizawa A, Nixon LL, Johnson CA, Ball LB, Jack E, Kang DS. Surveillance for asthma-United States, 1960-1995. MMWR 1998;47:1-27.
2. von Mutius E. The burden of childhood asthma. Arch Dis Child [Suppl] 2000;82:2-5.
3. National Heart, Lung, and Blood Institute/World Health Organization. Global Initiative for Asthma. Global strategy for asthma management and prevention. Publication no. 02-3659. Bethesda, MD: National Institutes of Health; 2002.
4. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, on behalf of GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
5. Frolund L, Madsen F, Svendsen UG, Weeke B. Comparison of two aerosols containing both fenoterol and ipratropium in a high (Duovent) and low (Berodual) concentration, respectively. Respiration [Suppl] 1986;50:270-273.
6. Philip-Joet F, Reynaud-Gaubert M, Jirou-Najou JL, Arnaud A. Comparison of Berodual and salbutamol in asthma: a multicenter evaluation. Respiration 1990;57:379-383.
7. Klabuschnigg A, Horak F, Rottensteiner K, Weissenbacher G, Vogt R. Combination aerosol for bronchial asthma in childhood [in German]. Padiatr Padol 1983;18:347-353.
8. Jedrys U, Kurzawa R, Haluszka J, Smieszek J, Doniec Z, Willim G. Evaluation of the bronchodilatory activity of Berodual and its components: fenoterol and ipratropium bromide in children with bronchial asthma [in Polish]. Pneumonol Alergol Pol 1994;62:615-622.
9. Baculard A. Role of Bronchodual in the long-term treatment of asthma in children [in French]. Arch Pediatr [Suppl] 1995;2:149-153.
10. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986;41:118-124.
11. Bisgaard H. Delivery of inhaled medication to children. J Asthma 1997;34:443-467.
12. Powell CV, Everard ML. Treatment of childhood asthma. Options and rationale for inhaled therapy. Drugs 1998;55:237-252.
13. Zierenberg B, Eicher J, Dunne S, Freund B. Boehringer Ingelheim nebulizer BINEB®: a new approach to inhalation therapy. Respir Drug Deliv V 1996;5:187-193.
14. Zierenberg B. Optimizing the in vitro performance of Respimat®. J Aerosol Med [Suppl] 1999;12:19-24.
15. Hochrainer D, Hölz H. Comparison of cloud velocities delivered from Respimat® Soft Mist™ Inhaler or MDIs [abstract]. J Aerosol Med 2001;14:1-5.
16. Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebuliser. J Pharm Sci 1996;85:960-964.
17. Steed KP, Towse LJ, Freund B, Newman SP. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat® nebuliser. Eur J Pharm Sci 1997;5:55-61.
18. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines (Respimat®): comparison with conventional metered-dose inhalers with and without spacer devices. Chest 1998;113:957-963.
19. van Noord JA, Smeets JJ, Creemers JPHM, Greethorst LPM, Dewberry H, Cornelissen PJG. Delivery of fenoterol via Respimat®, a novel "soft mist" inhaler. Respiration 2000;67:672-678.
20. Goldberg J, Freund E, Beckers B, Hinzman R. Improved delivery of fenoterol plus ipratropium bromide using Respimat® compared with a conventional metered dose inhaler. Eur Respir J 2001;17:225-232.
21. Kunkel G, Magnussen H, Bergmann K-C, Juergens UR, De Mey C, Freund E, Hinzmann R, Beckers B. Respimat® (a new Soft Mist™ inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000;67:306-314.
22. Cotes JE, editor. Lung function. Assessment and application in medicine, 3rd ed. Oxford: Blackwell Scientific Publications; 1975.
23. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report of Working Party Standardisation of Pulmonary Lung Function Tests, European Community for Steel and Coal. Eur Respir J [Suppl] 1993;6:5-40.
24. Vincken W, Gerken F, Moonen DM, Banjte TA, Viljoen JJ. Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients [abstract]. Eur Respir J [Suppl] 2001;18:70.
25. Miszkiel KA, Beasley R, Rafferty P, Holgate ST. The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol 1988;25:157-163.
26. Zhang YG, Wright WJ, Tam WK, Nguyen-Dang TH, Salone CM, Woolcock AJ. Effect of inhaled preservatives on asthmatic subjects. II. Benzalkonium chloride. Am Rev Respir Dis 1990;141:1405-1408.
27. Beasley R, Fishwick D, Miles JF, Hendeles L. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 1998;18:130-139.